139 related articles for article (PubMed ID: 29462213)
1. Early detection of pancreatic cancer in mouse models using a novel antibody, TAB004.
Wu ST; Williams CD; Grover PA; Moore LJ; Mukherjee P
PLoS One; 2018; 13(2):e0193260. PubMed ID: 29462213
[TBL] [Abstract][Full Text] [Related]
2. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
3. Combining the Specific Anti-MUC1 Antibody TAB004 and Lip-MSA-IL-2 Limits Pancreatic Cancer Progression in Immune Competent Murine Models of Pancreatic Ductal Adenocarcinoma.
Dréau D; Moore LJ; Wu M; Roy LD; Dillion L; Porter T; Puri R; Momin N; Wittrup KD; Mukherjee P
Front Oncol; 2019; 9():330. PubMed ID: 31114758
[TBL] [Abstract][Full Text] [Related]
4. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer.
Bose M; Sanders A; De C; Zhou R; Lala P; Shwartz S; Mitra B; Brouwer C; Mukherjee P
Transl Res; 2023 Mar; 253():41-56. PubMed ID: 36031050
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
[TBL] [Abstract][Full Text] [Related]
6. A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.
Zhou R; Curry JM; Roy LD; Grover P; Haider J; Moore LJ; Wu ST; Kamesh A; Yazdanifar M; Ahrens WA; Leung T; Mukherjee P
Oncogene; 2016 Oct; 35(43):5608-5618. PubMed ID: 26804176
[TBL] [Abstract][Full Text] [Related]
7. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
8. Ductal pancreatic cancer in humans and mice.
Tuveson DA; Hingorani SR
Cold Spring Harb Symp Quant Biol; 2005; 70():65-72. PubMed ID: 16869739
[TBL] [Abstract][Full Text] [Related]
9. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer.
Mirus JE; Zhang Y; Li CI; Lokshin AE; Prentice RL; Hingorani SR; Lampe PD
Clin Cancer Res; 2015 Apr; 21(7):1764-71. PubMed ID: 25589628
[TBL] [Abstract][Full Text] [Related]
10. Screening for early pancreatic ductal adenocarcinoma: an urgent call!
Lee MX; Saif MW
JOP; 2009 Mar; 10(2):104-8. PubMed ID: 19287101
[TBL] [Abstract][Full Text] [Related]
11. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
Tinder TL; Subramani DB; Basu GD; Bradley JM; Schettini J; Million A; Skaar T; Mukherjee P
J Immunol; 2008 Sep; 181(5):3116-25. PubMed ID: 18713982
[TBL] [Abstract][Full Text] [Related]
12. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
Fukamachi K; Tanaka H; Hagiwara Y; Ohara H; Joh T; Iigo M; Alexander DB; Xu J; Long N; Takigahira M; Yanagihara K; Hino O; Saito I; Tsuda H
Biochem Biophys Res Commun; 2009 Dec; 390(3):636-41. PubMed ID: 19818733
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma.
McIntyre CA; Winter JM
Semin Oncol; 2015 Feb; 42(1):19-27. PubMed ID: 25726049
[TBL] [Abstract][Full Text] [Related]
14. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic MUC1 in PanIN-1.
Bara J; Forgue-Lafitte ME
Clin Cancer Res; 2008 Aug; 14(16):5306; author reply 5306-7. PubMed ID: 18698052
[No Abstract] [Full Text] [Related]
16. MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models.
Park JY; Hiroshima Y; Lee JY; Maawy AA; Hoffman RM; Bouvet M
PLoS One; 2015; 10(3):e0122100. PubMed ID: 25815753
[TBL] [Abstract][Full Text] [Related]
17. MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.
Tholey RM; Lal S; Jimbo M; Burkhart RA; Blanco FF; Cozzitorto JA; Eisenberg JD; Jiang W; Iacobuzio-Donahue CA; Witkiewicz AK; Glbert M; Yeo CJ; Brody JR; Sawicki JA; Winter JM
Mol Cancer Res; 2015 Mar; 13(3):439-48. PubMed ID: 25336517
[TBL] [Abstract][Full Text] [Related]
18. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Gold DV; Newsome G; Liu D; Goldenberg DM
Mol Cancer; 2013 Nov; 12(1):143. PubMed ID: 24257318
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
Fukuda A
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]